12:00 AM
 | 
Nov 22, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Remicade infliximab: Phase III data; sBLA under review; marketed to reduce the signs and symptoms of RA and to treat Crohns disease

X-ray data from 348 patients in Centocor’s Phase III ATTRACT trial showed no median progression of joint damage from baseline in patients treated with Remicade...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >